| Identification | Back Directory | [Name]
2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole | [CAS]
303727-31-3 | [Synonyms]
450
L-779
CS-1697
L-779450
Raf Kinase Inhibitor IV
2-Chloro-5-[2-Phenyl-5-(4-pyridinyl)-1H-imidazol-4-yl]phenol
2-chloro-5-[2-phenyl-4-(4-pyridinyl)-1H-imidazol-5-yl]phenol
2-Chloro-5-(2-phenyl-5-(pyridin-4-yl)-1H-iMidazol-4-yl)phenol
2-chloro-5-(2-phenyl-4-(pyridin-4-yl)-1H-imidazol-5-yl)phenol
Phenol, 2-chloro-5-[2-phenyl-4-(4-pyridinyl)-1H-iMidazol-5-yl]-
4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-1H-iMidazole
2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole
4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(pyridin-4-yl)-1H-iMidazole
2-(Phenyl)-4-(3-hydroxy-4-chlorophenyl)-5-(4-pyridyl)-1H-imidazole ISO 9001：2015 REACH | [Molecular Formula]
C20H14ClN3O | [MDL Number]
MFCD12828750 | [MOL File]
303727-31-3.mol | [Molecular Weight]
347.8 |
| Chemical Properties | Back Directory | [Boiling point ]
579.8±50.0 °C(Predicted) | [density ]
1.335±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO:44.67(Max Conc. mg/mL);128.44(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);86.26(Max Conc. mM)
DMF:PBS (pH 7.2) (1:7):0.12(Max Conc. mg/mL);0.35(Max Conc. mM)
Ethanol:2.0(Max Conc. mg/mL);5.75(Max Conc. mM) | [form ]
Powder | [pka]
8.09±0.10(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Raf kinase inhibitor, a potential treatment for neurotraumatic diseases. Its effects also suppress DNA synthesis and induce apoptosis in targeted cells, presenting new applications in treating certain types of cancers. | [Definition]
ChEBI: 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol is a member of imidazoles. | [Biological Activity]
Potent, ATP-competitive Raf kinase inhibitor (IC 50 = 10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38 α , GSK3 β and Lck respectively. Suppresses DNA synthesis and induces apoptosis in cells that proliferate in response to Raf-1 and A-Raf but not B-Raf. |
|
|